The roles of TGFβ in the tumour microenvironment (original) (raw)

• Siegel, P. M. & Massague, J. Cytostatic and apoptotic actions of TGFβ in homeostasis and cancer. Nature Rev. Cancer 3, 807–821 (2003).
  Article CAS Google Scholar
• Massague, J. G1 cell-cycle control and cancer. Nature 432, 298–306 (2004).
  Article CAS PubMed Google Scholar
• Gorsch, S. M., Memoli, V. A., Stukel, T. A., Gold, L. I. & Arrick, B. A. Immunohistochemical staining for transforming growth factor β 1 associates with disease progression in human breast cancer. Cancer Res. 52, 6949–6952 (1992).
  CAS PubMed Google Scholar
• Hasegawa, Y. et al. Transforming growth factor-β1 level correlates with angiogenesis, tumor progression, and prognosis in patients with nonsmall cell lung carcinoma. Cancer 91, 964–971 (2001).
  Article CAS PubMed Google Scholar
• Miettinen, P. J., Ebner, R., Lopez, A. R. & Derynck, R. TGF-β induced transdifferentiation of mammary epithelial cells to mesenchymal cells: involvement of type I receptors. J. Cell Biol. 127, 2021–2036 (1994).
  Article CAS PubMed Google Scholar
• Caulin, C., Scholl, F. G., Frontelo, P., Gamallo, C. & Quintanilla, M. Chronic exposure of cultured transformed mouse epidermal cells to transforming growth factor-β 1 induces an epithelial-mesenchymal transdifferentiation and a spindle tumoral phenotype. Cell Growth Differ. 6, 1027–1035 (1995).
  CAS PubMed Google Scholar
• Walker, R. A., Dearing, S. J. & Gallacher, B. Relationship of transforming growth factor β 1 to extracellular matrix and stromal infiltrates in invasive breast carcinoma. Br. J. Cancer 69, 1160–1165 (1994).
  Article CAS PubMed PubMed Central Google Scholar
• Wikstrom, P., Stattin, P., Franck-Lissbrant, I., Damber, J. E. & Bergh, A. Transforming growth factor β1 is associated with angiogenesis, metastasis, and poor clinical outcome in prostate cancer. Prostate 37, 19–29 (1998).
  Article CAS PubMed Google Scholar
• Hazelbag, S., Gorter, A., Kenter, G. G., van den Broek, L. & Fleuren, G. Transforming growth factor-β1 induces tumor stroma and reduces tumor infiltrate in cervical cancer. Hum. Pathol. 33, 1193–1199 (2002).
  Article CAS PubMed Google Scholar
• Bierie, B. & Moses, H. L. TGF-β and cancer. Cytokine Growth Factor Rev. 17, 29–40 (2006).
  Article CAS PubMed Google Scholar
• Massague, J. TGFβ signalling in context. Nature Rev. Mol. Cell Biol. 13, 616–630 (2012).
  Article CAS Google Scholar
• Rifkin, D. B. Latent transforming growth factor-β (TGF-β) binding proteins: orchestrators of TGF-β availability. J. Biol. Chem. 280, 7409–7412 (2005).
  Article CAS PubMed Google Scholar
• Shi, Y. & Massague, J. Mechanisms of TGF-β signaling from cell membrane to the nucleus. Cell 113, 685–700 (2003).
  Article CAS PubMed Google Scholar
• Stenvers, K. L. et al. Heart and liver defects and reduced transforming growth factor β2 sensitivity in transforming growth factor β type III receptor-deficient embryos. Mol. Cell. Biol. 23, 4371–4385 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Moustakas, A. et al. The transforming growth factor β receptors types I, II, and III form hetero-oligomeric complexes in the presence of ligand. J. Biol. Chem. 268, 22215–22218 (1993).
  CAS PubMed Google Scholar
• Derynck, R. & Zhang, Y. E. Smad-dependent and Smad-independent pathways in TGF-β family signalling. Nature 425, 577–584 (2003).
  Article CAS PubMed Google Scholar
• Feng, X. H. & Derynck, R. Specificity and versatility in TGF-β signaling through Smads. Annu. Rev. Cell Dev. Biol. 21, 659–693 (2005).
  Article CAS PubMed Google Scholar
• Schmierer, B. & Hill, C. S. Kinetic analysis of Smad nucleocytoplasmic shuttling reveals a mechanism for transforming growth factor β-dependent nuclear accumulation of Smads. Mol. Cell. Biol. 25, 9845–9858 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Moustakas, A. & Heldin, C. H. Non-Smad TGF-β signals. J. Cell Sci. 118, 3573–3584 (2005).
  Article CAS PubMed Google Scholar
• Massague, J. & Gomis, R. R. The logic of TGFβ signaling. FEBS Lett. 580, 2811–2820 (2006).
  Article CAS PubMed Google Scholar
• Ewen, M. E., Oliver, C. J., Sluss, H. K., Miller, S. J. & Peeper, D. S. p53-dependent repression of CDK4 translation in TGF-β-induced G1 cell-cycle arrest. Genes Dev. 9, 204–217 (1995).
  Article CAS PubMed Google Scholar
• Polyak, K. et al. p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-β and contact inhibition to cell cycle arrest. Genes Dev. 8, 9–22 (1994).
  Article CAS PubMed Google Scholar
• Hannon, G. J. & Beach, D. p15INK4B is a potential effector of TGF-β-induced cell cycle arrest. Nature 371, 257–261 (1994).
  Article CAS PubMed Google Scholar
• Pardali, K. & Moustakas, A. Actions of TGF-β as tumor suppressor and pro-metastatic factor in human cancer. Biochim. Biophys. Acta 1775, 21–62 (2007).
  CAS PubMed Google Scholar
• Bottinger, E. P. et al. Expression of a dominant-negative mutant TGF-β type II receptor in transgenic mice reveals essential roles for TGF-β in regulation of growth and differentiation in the exocrine pancreas. EMBO J. 16, 2621–2633 (1997).
  Article CAS PubMed PubMed Central Google Scholar
• Amendt, C., Schirmacher, P., Weber, H. & Blessing, M. Expression of a dominant negative type II TGF-β receptor in mouse skin results in an increase in carcinoma incidence and an acceleration of carcinoma development. Oncogene 17, 25–34 (1998).
  Article CAS PubMed Google Scholar
• Huber, M. A., Kraut, N. & Beug, H. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr. Opin. Cell Biol. 17, 548–558 (2005).
  Article CAS PubMed Google Scholar
• Dumont, N., Bakin, A. V. & Arteaga, C. L. Autocrine transforming growth factor-β signaling mediates Smad-independent motility in human cancer cells. J. Biol. Chem. 278, 3275–3285 (2003).
  Article CAS PubMed Google Scholar
• Giampieri, S. et al. Localized and reversible TGFβ signalling switches breast cancer cells from cohesive to single cell motility. Nature Cell Biol. 11, 1287–1296 (2009). This paper shows the identification of TGFβ signalling as a mediator of single-cell invasion and of vascular metastasis, with the cells that are unable to respond to TGFβ showing a cohesive migratory phenotype.
  Article CAS PubMed Google Scholar
• Muraoka-Cook, R. S. et al. Activated type I TGFβ receptor kinase enhances the survival of mammary epithelial cells and accelerates tumor progression. Oncogene 25, 3408–3423 (2006).
  Article CAS PubMed Google Scholar
• Safina, A., Vandette, E. & Bakin, A. V. ALK5 promotes tumor angiogenesis by upregulating matrix metalloproteinase-9 in tumor cells. Oncogene 26, 2407–2422 (2007).
  Article CAS PubMed Google Scholar
• Schniewind, B. et al. Dissecting the role of TGF-β type I receptor/ALK5 in pancreatic ductal adenocarcinoma: Smad activation is crucial for both the tumor suppressive and prometastatic function. Oncogene 26, 4850–4862 (2007).
  Article CAS PubMed Google Scholar
• Esquela-Kerscher, A. & Slack, F. J. Oncomirs — microRNAs with a role in cancer. Nature Rev. Cancer 6, 259–269 (2006).
  Article CAS Google Scholar
• Yang, P. et al. TGF-β-miR-34a-CCL22 signaling-induced Treg cell recruitment promotes venous metastases of HBV-positive hepatocellular carcinoma. Cancer Cell 22, 291–303 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Davis, B. N., Hilyard, A. C., Lagna, G. & Hata, A. SMAD proteins control DROSHA-mediated microRNA maturation. Nature 454, 56–61 (2008). This is the first established link between SMAD activity and the maturation of pri-miRNA through DROSHA, specifically following BMP treatment.
  Article CAS PubMed PubMed Central Google Scholar
• Wang, J., Wang, Y., Ma, Y., Lan, Y. & Yang, X. Transforming growth factor β-regulated microRNA-29a promotes angiogenesis through targeting the phosphatase and tensin homolog in endothelium. J. Biol. Chem. 288, 10418–10426 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Liu, Y. et al. MicroRNA-494 is required for the accumulation and functions of tumor-expanded myeloid-derived suppressor cells via targeting of PTEN. J. Immunol. 188, 5500–5510 (2012).
  Article CAS PubMed Google Scholar
• Wang, S. E. et al. Transforming growth factor β engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumab. Mol. Cell. Biol. 28, 5605–5620 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Sartor, M. A. et al. ConceptGen: a gene set enrichment and gene set relation mapping tool. Bioinformatics 26, 456–463 (2010).
  Article CAS PubMed Google Scholar
• Hills, C. E., Willars, G. B. & Brunskill, N. J. Proinsulin C-peptide antagonizes the profibrotic effects of TGF-β1 via up-regulation of retinoic acid and HGF-related signaling pathways. Mol. Endocrinol. 24, 822–831 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Maupin, K. A. et al. Glycogene expression alterations associated with pancreatic cancer epithelial–mesenchymal transition in complementary model systems. PLoS ONE 5, e13002 (2010).
  Article PubMed PubMed Central CAS Google Scholar
• Coulouarn, C., Factor, V. M. & Thorgeirsson, S. S. Transforming growth factor-β gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer. Hepatology 47, 2059–2067 (2008).
  Article CAS PubMed Google Scholar
• Massague, J. TGFβ in cancer. Cell 134, 215–230 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Mima, K. et al. Epithelial–mesenchymal transition expression profiles as a prognostic factor for disease-free survival in hepatocellular carcinoma: clinical significance of transforming growth factor-β signaling. Oncol. Lett. 5, 149–154 (2013).
  Article PubMed Google Scholar
• Forrester, E. et al. Effect of conditional knockout of the type II TGF-β receptor gene in mammary epithelia on mammary gland development and polyomavirus middle T antigen induced tumor formation and metastasis. Cancer Res. 65, 2296–2302 (2005).
  Article CAS PubMed Google Scholar
• Lu, S. L. et al. Loss of transforming growth factor-β type II receptor promotes metastatic head-and-neck squamous cell carcinoma. Genes Dev. 20, 1331–1342 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Paiva, C. E. et al. Absence of TGF-βRII predicts bone and lung metastasis and is associated with poor prognosis in stage III breast tumors. Cancer Biomark 11, 209–217 (2012). This paper is a histochemical study of TGFβ signalling in breast cancer and shows a correlation between decreased signalling in the tumour epithelium and increased tumour metastasis to the lungs and the bone. This article also indicates that low TGFBR2 levels indicate poor disease-free and overall survival.
  Article CAS PubMed Google Scholar
• Levy, L. & Hill, C. S. Alterations in components of the TGF-β superfamily signaling pathways in human cancer. Cytokine Growth Factor Rev. 17, 41–58 (2006).
  Article CAS PubMed Google Scholar
• Malkoski, S. P. et al. Loss of transforming growth factor β type II receptor increases aggressive tumor behavior and reduces survival in lung adenocarcinoma and squamous cell carcinoma. Clin. Cancer Res. 18, 2173–2183 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Bierie, B. & Moses, H. L. Tumour microenvironment: TGFβ: the molecular Jekyll and Hyde of cancer. Nature Rev. Cancer 6, 506–520 (2006).
  Article CAS PubMed Google Scholar
• Yang, L. et al. Abrogation of TGF β signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell 13, 23–35 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Ijichi, H. et al. Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma. J. Clin. Invest. 121, 4106–4117 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Lin, S. et al. Attenuation of TGF-β signaling suppresses premature senescence in a p21-dependent manner and promotes oncogenic Ras-mediated metastatic transformation in human mammary epithelial cells. Mol. Biol. Cell 23, 1569–1581 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Gewin, L. et al. TGF-β receptor deletion in the renal collecting system exacerbates fibrosis. J. Am. Soc. Nephrol. 21, 1334–1343 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Bierie, B. et al. Abrogation of TGF-β signaling enhances chemokine production and correlates with prognosis in human breast cancer. J. Clin. Invest. 119, 1571–1582 (2009). This paper is the first to establish of a poor clinical outcome related to the genetic changes, particularly the altered chemokine expression, that occur following ablation of TGFβ signalling in the tumour epithelium.
  Article CAS PubMed PubMed Central Google Scholar
• Finak, G. et al. Stromal gene expression predicts clinical outcome in breast cancer. Nature Med. 14, 518–527 (2008). This is the first identification of a link between stromal gene expression changes and the outcome of patients with breast cancer.
  Article CAS PubMed Google Scholar
• Knudsen, E. S. et al. Progression of ductal carcinoma in situ to invasive breast cancer is associated with gene expression programs of EMT and myoepithelia. Breast Cancer Res. Treat. 133, 1009–1024 (2012).
  Article CAS PubMed Google Scholar
• Vogelstein, B. et al. Genetic alterations during colorectal-tumor development. N. Engl. J. Med. 319, 525–532 (1988).
  Article CAS PubMed Google Scholar
• Hanahan, D. & Coussens, L. M. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 21, 309–322 (2012).
  Article CAS PubMed Google Scholar
• Nombela-Arrieta, C., Ritz, J. & Silberstein, L. E. The elusive nature and function of mesenchymal stem cells. Nature Rev. Mol. Cell Biol. 12, 126–131 (2011).
  Article CAS Google Scholar
• Watabe, T. & Miyazono, K. Roles of TGF-β family signaling in stem cell renewal and differentiation. Cell Res. 19, 103–115 (2009).
  Article CAS PubMed Google Scholar
• Cuiffo, B. G. & Karnoub, A. E. Mesenchymal stem cells in tumor development: emerging roles and concepts. Cell Adh. Migr. 6, 220–230 (2012).
  Article PubMed PubMed Central Google Scholar
• Tang, Y. et al. TGF-β1-induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nature Med. 15, 757–765 (2009).
  Article CAS PubMed Google Scholar
• Zhao, L. & Hantash, B. M. TGF-β1 regulates differentiation of bone marrow mesenchymal stem cells. Vitam. Horm. 87, 127–141 (2011).
  Article CAS PubMed Google Scholar
• Kurpinski, K. et al. Transforming growth factor-β and notch signaling mediate stem cell differentiation into smooth muscle cells. Stem Cells 28, 734–742 (2010).
  Article CAS PubMed Google Scholar
• Wan, M. et al. Injury-activated transforming growth factor β controls mobilization of mesenchymal stem cells for tissue remodeling. Stem Cells 30, 2498–2511 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Jung, Y. et al. Recruitment of mesenchymal stem cells into prostate tumours promotes metastasis. Nature Commun. 4, 1795 (2013).
  Article CAS Google Scholar
• Quante, M. et al. Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth. Cancer Cell 19, 257–272 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Karnoub, A. E. et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 449, 557–563 (2007).
  Article CAS PubMed Google Scholar
• Spaeth, E. L. et al. Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. PLoS ONE 4, e4992 (2009).
  Article PubMed PubMed Central CAS Google Scholar
• Shangguan, L. et al. Inhibition of TGF-β/Smad signaling by BAMBI blocks differentiation of human mesenchymal stem cells to carcinoma-associated fibroblasts and abolishes their protumor effects. Stem Cells 30, 2810–2819 (2012).
  Article PubMed CAS Google Scholar
• Verona, E. V. et al. Transforming growth factor-β signaling in prostate stromal cells supports prostate carcinoma growth by up-regulating stromal genes related to tissue remodeling. Cancer Res. 67, 5737–5746 (2007).
  Article CAS PubMed Google Scholar
• Border, W. A. & Noble, N. A. Transforming growth factor β in tissue fibrosis. N. Engl. J. Med. 331, 1286–1292 (1994).
  Article CAS PubMed Google Scholar
• Leask, A. & Abraham, D. J. TGF-β signaling and the fibrotic response. FASEB J. 18, 816–827 (2004).
  Article CAS PubMed Google Scholar
• Boyd, N. F. et al. Mammographic density and the risk and detection of breast cancer. N. Engl. J. Med. 356, 227–236 (2007).
  Article CAS PubMed Google Scholar
• Desmouliere, A., Geinoz, A., Gabbiani, F. & Gabbiani, G. Transforming growth factor-β 1 induces αalpha-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts. J. Cell Biol. 122, 103–111 (1993).
  Article CAS PubMed Google Scholar
• Sime, P. J., Xing, Z., Graham, F. L., Csaky, K. G. & Gauldie, J. Adenovector-mediated gene transfer of active transforming growth factor-β1 induces prolonged severe fibrosis in rat lung. J. Clin. Invest. 100, 768–776 (1997).
  Article CAS PubMed PubMed Central Google Scholar
• Sonnylal, S. et al. Postnatal induction of transforming growth factor β signaling in fibroblasts of mice recapitulates clinical, histologic, and biochemical features of scleroderma. Arthritis Rheum. 56, 334–344 (2007).
  Article CAS PubMed Google Scholar
• Navab, R. et al. Prognostic gene-expression signature of carcinoma-associated fibroblasts in non-small cell lung cancer. Proc. Natl Acad. Sci. USA 108, 7160–7165 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Hawinkels, L. J. et al. Interaction with colon cancer cells hyperactivates TGF-β signaling in cancer-associated fibroblasts. Oncogene http://dx.doi.org/10.1038/onc.2012.536 (2012).
• Calon, A. et al. Dependency of colorectal cancer on a TGF-β-driven program in stromal cells for metastasis initiation. Cancer Cell 22, 571–584 (2012). This paper establishes TGFβ-responsive stromal signalling, especially from fibroblasts, as a driver of tumour progression and metastasis. This stromal programme could be blocked with the addition of TGFβ inhibitors to slow tumour growth.
  Article CAS PubMed PubMed Central Google Scholar
• Bhowmick, N. A. et al. TGF-β signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 303, 848–851 (2004). This is the first report showing that genetic mutations in stromal fibroblast can result in the development of carcinoma formation from the adjacent epithelium.
  Article CAS PubMed Google Scholar
• Cheng, N. et al. Loss of TGF-β type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGF-alpha-, MSP- and HGF-mediated signaling networks. Oncogene 24, 5053–5068 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Franco, O. E. et al. Altered TGF-β signaling in a subpopulation of human stromal cells promotes prostatic carcinogenesis. Cancer Res. 71, 1272–1281 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Meng, W. et al. Downregulation of TGF-β receptor types II and III in oral squamous cell carcinoma and oral carcinoma-associated fibroblasts. BMC Cancer 11, 88 (2011).
  Article PubMed PubMed Central CAS Google Scholar
• Xu, B. J. et al. Quantitative analysis of the secretome of TGF-β signaling-deficient mammary fibroblasts. Proteomics 10, 2458–2470 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Bacman, D. et al. TGF-β receptor 2 downregulation in tumour-associated stroma worsens prognosis and high-grade tumours show more tumour-associated macrophages and lower TGF-β1 expression in colon carcinoma: a retrospective study. BMC Cancer 7, 156 (2007).
  Article PubMed PubMed Central CAS Google Scholar
• Achyut, B. R. et al. Inflammation-mediated genetic and epigenetic alterations drive cancer development in the neighboring epithelium upon stromal abrogation of TGF-β signaling. PLoS Genet. 9, e1003251 (2013). This is an interesting paper showing that inflammatory infiltrates mediate the pro-tumorigenic functions of fibroblasts that lack TGFβ signalling, particularly through the induction of epigenetic silencing of p15 and p16 in epithelial cells.
  Article CAS PubMed PubMed Central Google Scholar
• Flavell, R. A., Sanjabi, S., Wrzesinski, S. H. & Licona-Limon, P. The polarization of immune cells in the tumour environment by TGFβ. Nature Rev. Immunol. 10, 554–567 (2010).
  Article CAS Google Scholar
• Gigante, M., Gesualdo, L. & Ranieri, E. TGF-β: a master switch in tumor immunity. Curr. Pharm. Des. 18, 4126–4134 (2012).
  Article CAS PubMed Google Scholar
• Gong, D. et al. TGFβ signaling plays a critical role in promoting alternative macrophage activation. BMC Immunol. 13, 31 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Murray, P. J. & Wynn, T. A. Protective and pathogenic functions of macrophage subsets. Nature Rev. Immunol. 11, 723–737 (2011).
  Article CAS Google Scholar
• Fridlender, Z. G. & Albelda, S. M. Tumor-associated neutrophils: friend or foe? Carcinogenesis 33, 949–955 (2012).
  Article CAS PubMed Google Scholar
• Fridlender, Z. G. et al. Polarization of tumor-associated neutrophil phenotype by TGF-β: “N1” versus “N2” TAN. Cancer Cell 16, 183–194 (2009). This is the first paper to establish an N2 neutrophil phenotype and to show that this phenotype is driven by TGFβ signalling. These neutrophils promote tumour progression through the inhibition of antitumorigenic CD8+ T cell activity.
  Article CAS PubMed PubMed Central Google Scholar
• Marcoe, J. P. et al. TGF-β is responsible for NK cell immaturity during ontogeny and increased susceptibility to infection during mouse infancy. Nature Immunol. 13, 843–850 (2012). This paper identifies TGFβ as a factor that inhibits NK cell maturation and shows that loss of TGFβ signalling is a mark of stage F NK cell development.
  Article CAS Google Scholar
• Leavy, O. Maturation and function of NK cells. Nature Rev. Immunol. 12, 150 (2012).
  Article CAS Google Scholar
• Laouar, Y., Sutterwala, F. S., Gorelik, L. & Flavell, R. A. Transforming growth factor-β controls T helper type 1 cell development through regulation of natural killer cell interferon-γ. Nature Immunol. 6, 600–607 (2005).
  Article CAS Google Scholar
• Tanaka, H. et al. Transforming growth factor β signaling inhibitor, SB-431542, induces maturation of dendritic cells and enhances anti-tumor activity. Oncol. Rep. 24, 1637–1643 (2010).
  CAS PubMed Google Scholar
• Novitskiy, S. V. et al. Deletion of TGF-β signaling in myeloid cells enhances their anti-tumorigenic properties. J. Leukoc. Biol. 92, 641–651 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Perrot, I. et al. Dendritic cells infiltrating human non-small cell lung cancer are blocked at immature stage. J. Immunol. 178, 2763–2769 (2007).
  Article CAS PubMed Google Scholar
• Roncarolo, M. G., Levings, M. K. & Traversari, C. Differentiation of T regulatory cells by immature dendritic cells. J. Exp. Med. 193, F5–9 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Shull, M. M. et al. Targeted disruption of the mouse transforming growth factor-β 1 gene results in multifocal inflammatory disease. Nature 359, 693–699 (1992).
  Article CAS PubMed PubMed Central Google Scholar
• Kulkarni, A. B. et al. Transforming growth factor β 1 null mutation in mice causes excessive inflammatory response and early death. Proc. Natl Acad. Sci. USA 90, 770–774 (1993).
  Article CAS PubMed PubMed Central Google Scholar
• Marie, J. C., Liggitt, D. & Rudensky, A. Y. Cellular mechanisms of fatal early-onset autoimmunity in mice with the T cell-specific targeting of transforming growth factor-β receptor. Immunity 25, 441–454 (2006).
  Article CAS PubMed Google Scholar
• Bommireddy, R. et al. Self-antigen recognition by TGF β1-deficient T cells causes their activation and systemic inflammation. Lab Invest. 86, 1008–1019 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Li, M. O. & Flavell, R. A. TGF-β: a master of all T cell trades. Cell 134, 392–404 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Chen, W. et al. Conversion of peripheral CD4+CD25− naive T cells to CD4+CD25+ regulatory T cells by TGF-β induction of transcription factor Foxp3. J. Exp. Med. 198, 1875–1886 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Tone, Y. et al. Smad3 and NFAT cooperate to induce Foxp3 expression through its enhancer. Nature Immunol. 9, 194–202 (2008).
  Article CAS Google Scholar
• Chen, Y., Kuchroo, V. K., Inobe, J., Hafler, D. A. & Weiner, H. L. Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science 265, 1237–1240 (1994).
  Article CAS PubMed Google Scholar
• Vignali, D. A., Collison, L. W. & Workman, C. J. How regulatory T cells work. Nature Rev. Immunol. 8, 523–532 (2008).
  Article CAS Google Scholar
• von Boehmer, H. & Daniel, C. Therapeutic opportunities for manipulating TReg cells in autoimmunity and cancer. Nature Rev. Drug Discov. 12, 51–63 (2013).
  Article CAS Google Scholar
• Mangan, P. R. et al. Transforming growth factor-β induces development of the TH17 lineage. Nature 441, 231–234 (2006). This paper identifies TGFβ as a primary factor in the induced differentiation of T H 17 cell commitment in a subpopulation of T cells — a process that is independent of T Reg cells.
  Article CAS PubMed Google Scholar
• Ivanov, I. I. et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 126, 1121–1133 (2006).
  Article CAS PubMed Google Scholar
• Whiteside, T. L. What are regulatory T cells (Treg) regulating in cancer and why? Semin. Cancer Biol. 22, 327–334 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Kim, B. G. et al. Smad4 signalling in T cells is required for suppression of gastrointestinal cancer. Nature 441, 1015–1019 (2006). This seminal paper identifies of TGFβ superfamily signalling in T cells as an inhibitor of tumour progression due to the suppression of the expression of T H 1 cytokines.
  Article CAS PubMed Google Scholar
• Ghoreschi, K. et al. Generation of pathogenic Th17 cells in the absence of TGF-β signalling. Nature 467, 967–971 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Jain, R. K. Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J. Clin. Oncol. 31, 2205–2218 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Huang, Y. et al. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc. Natl Acad. Sci. USA 109, 17561–17566 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Liu, J. et al. TGF-β blockade improves the distribution and efficacy of therapeutics in breast carcinoma by normalizing the tumor stroma. Proc. Natl Acad. Sci. USA 109, 16618–16623 (2012). This is an interesting paper showing that TGFβ inhibition-normalized breast tumour stroma enhances chemotherapeutic efficacy.
  Article CAS PubMed PubMed Central Google Scholar
• Diop-Frimpong, B., Chauhan, V. P., Krane, S., Boucher, Y. & Jain, R. K. Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors. Proc. Natl Acad. Sci. USA 108, 2909–2914 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Mead, A. L., Wong, T. T., Cordeiro, M. F., Anderson, I. K. & Khaw, P. T. Evaluation of anti-TGF-β2 antibody as a new postoperative anti-scarring agent in glaucoma surgery. Invest. Ophthalmol. Vis. Sci. 44, 3394–3401 (2003).
  Article PubMed Google Scholar
• Bogdahn, U. et al. Targeted therapy for high-grade glioma with the TGF-β2 inhibitor trabedersen: results of a randomized and controlled phase IIb study. Neuro Oncol. 13, 132–142 (2011).
  Article CAS PubMed Google Scholar
• Schlingensiepen, K. H. et al. Transforming growth factor-β 2 gene silencing with trabedersen in pancreatic cancer. Cancer Sci. 102, 1193–1200 (2011).
  Article CAS PubMed Google Scholar
• Roldan Urgoiti, G. B., Singh, A. D. & Easaw, J. C. Extended adjuvant temozolomide for treatment of newly diagnosed glioblastoma multiforme. J. Neurooncol. 108, 173–177 (2012).
  Article CAS PubMed Google Scholar
• Akhurst, R. J. & Hata, A. Targeting the TGFβ signalling pathway in disease. Nature Rev. Drug Discov. 11, 790–811 (2012).
  Article CAS Google Scholar
• Zhong, Z. et al. Anti-transforming growth factor β receptor II antibody has therapeutic efficacy against primary tumor growth and metastasis through multieffects on cancer, stroma, and immune cells. Clin. Cancer Res. 16, 1191–1205 (2010). This paper shows that anti-TGFβ therapeutics slow tumour progression by modulating the composition of immune cell infiltrates in favour of an antitumorigenic phenotype.
  Article CAS PubMed Google Scholar
• Uhl, M. et al. SD-208, a novel transforming growth factor β receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res. 64, 7954–7961 (2004).
  Article CAS PubMed Google Scholar
• Kim, S. et al. Systemic blockade of transforming growth factor-β signaling augments the efficacy of immunogene therapy. Cancer Res. 68, 10247–10256 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Foster, A. E. et al. Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-β receptor. J. Immunother. 31, 500–505 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Azad, N., Zahnow, C. A., Rudin, C. M. & Baylin, S. B. The future of epigenetic therapy in solid tumours-lessons from the past. Nature Rev. Clin. Oncol. 10, 256–266 (2013).
  Article CAS Google Scholar
• Jones, P. A. & Baylin, S. B. The fundamental role of epigenetic events in cancer. Nature Rev. Genet. 3, 415–428 (2002).
  Article CAS PubMed Google Scholar
• Zhang, Q. et al. TGF-β regulates DNA methyltransferase expression in prostate cancer, correlates with aggressive capabilities, and predicts disease recurrence. PLoS ONE 6, e25168 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Ammanamanchi, S. & Brattain, M. G. Restoration of transforming growth factor-β signaling through receptor RI induction by histone deacetylase activity inhibition in breast cancer cells. J. Biol. Chem. 279, 32620–32625 (2004).
  Article CAS PubMed Google Scholar
• Kang, S. H. et al. Transcriptional repression of the transforming growth factor-β type I receptor gene by DNA methylation results in the development of TGF-β resistance in human gastric cancer. Oncogene 18, 7280–7286 (1999).
  Article CAS PubMed Google Scholar
• Osada, H. et al. Heterogeneous transforming growth factor (TGF)-β unresponsiveness and loss of TGF-β receptor type II expression caused by histone deacetylation in lung cancer cell lines. Cancer Res. 61, 8331–8339 (2001).
  CAS PubMed Google Scholar
• Khin, S. S. et al. Epigenetic alteration by DNA promoter hypermethylation of genes related to transforming growth factor-β (TGF-B) signaling in cancer. Cancers 3, 982–993 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Yeh, K. T. et al. Aberrant TGFβ/SMAD4 signaling contributes to epigenetic silencing of a putative tumor suppressor, RunX1T1 in ovarian cancer. Epigenetics 6, 727–739 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Papageorgis, P. et al. Smad signaling is required to maintain epigenetic silencing during breast cancer progression. Cancer Res. 70, 968–978 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Pan, X., Chen, Z., Huang, R., Yao, Y. & Ma, G. Transforming growth factor β1 induces the expression of collagen type I by DNA methylation in cardiac fibroblasts. PLoS ONE 8, e60335 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Hu, B., Gharaee-Kermani, M., Wu, Z. & Phan, S. H. Epigenetic regulation of myofibroblast differentiation by DNA methylation. Am. J. Pathol. 177, 21–28 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Ross, S. et al. Smads orchestrate specific histone modifications and chromatin remodeling to activate transcription. EMBO J. 25, 4490–4502 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Sun, G. et al. Epigenetic histone methylation modulates fibrotic gene expression. J. Am. Soc. Nephrol. 21, 2069–2080 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Glenisson, W., Castronovo, V. & Waltregny, D. Histone deacetylase 4 is required for TGFβ1-induced myofibroblastic differentiation. Biochim. Biophys. Acta 1773, 1572–1582 (2007).
  Article CAS PubMed Google Scholar
• Diaz-Valdes, N. et al. Induction of monocyte chemoattractant protein-1 and interleukin-10 by TGFβ1 in melanoma enhances tumor infiltration and immunosuppression. Cancer Res. 71, 812–821 (2011).
  Article CAS PubMed Google Scholar
• Terabe, M. et al. Synergistic enhancement of CD8+ T cell-mediated tumor vaccine efficacy by an anti-transforming growth factor-β monoclonal antibody. Clin. Cancer Res. 15, 6560–6569 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Hardee, M. E. et al. Resistance of glioblastoma-initiating cells to radiation mediated by the tumor microenvironment can be abolished by inhibiting transforming growth factor-β. Cancer Res. 72, 4119–4129 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Noma, K. et al. The essential role of fibroblasts in esophageal squamous cell carcinoma-induced angiogenesis. Gastroenterology 134, 1981–1993 (2008).
  Article PubMed Google Scholar
• Mazzocca, A., Fransvea, E., Lavezzari, G., Antonaci, S. & Giannelli, G. Inhibition of transforming growth factor β receptor I kinase blocks hepatocellular carcinoma growth through neo-angiogenesis regulation. Hepatology 50, 1140–1151 (2009).
  Article CAS PubMed Google Scholar
• Zhang, M. et al. Trimodal glioblastoma treatment consisting of concurrent radiotherapy, temozolomide, and the novel TGF-β receptor I kinase inhibitor LY2109761. Neoplasia 13, 537–549 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Tran, T. T. et al. Inhibiting TGF-β signaling restores immune surveillance in the SMA-560 glioma model. Neuro Oncol. 9, 259–270 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Garrison, K. et al. The small molecule TGF-β signaling inhibitor SM16 synergizes with agonistic OX40 antibody to suppress established mammary tumors and reduce spontaneous metastasis. Cancer Immunol. Immunother. 61, 511–521 (2012).
  Article CAS PubMed Google Scholar
• Lucas, P. J., Kim, S. J., Melby, S. J. & Gress, R. E. Disruption of T. cell homeostasis in mice expressing a T. cell-specific dominant negative transforming growth factor β II receptor. J. Exp. Med. 191, 1187–1196 (2000).
  Article CAS PubMed PubMed Central Google Scholar